Melanoma and microbiota: Current understanding and future directions

Bertrand Routy; Tanisha Jackson; Laura Mählmann; Christina K. Baumgartner; Martin Blaser; Allyson Byrd; Nathalie Corvaia; Kasey Couts; Diwakar Davar; Lisa Derosa; Howard C. Hang; Geke Hospers; Morten Isaksen; Guido Kroemer; Florent Malard; Kathy D. McCoy; Marlies Meisel; Sumanta Pal; Ze'ev Ronai; Eran Segal; Gregory D. Sepich-Poore; Fyza Shaikh; Randy F. Sweis; Giorgio Trinchieri; Marcel van den Brink; Rinse K. Weersma; Katrine Whiteson; Liping Zhao; Jennifer McQuade; Hassane Zarour; Laurence Zitvogel

doi:10.1016/j.ccell.2023.12.003

Melanoma and microbiota: Current understanding and future directions

Bertrand Routy, Tanisha Jackson, Laura Mählmann, Christina K. Baumgartner, Martin Blaser, Allyson Byrd, Nathalie Corvaia, Kasey Couts, Diwakar Davar, Lisa Derosa, Howard C. Hang, Geke Hospers, Morten Isaksen, Guido Kroemer, Florent Malard, Kathy D. McCoy, Marlies Meisel, Sumanta Pal, Ze'ev Ronai, Eran SegalGregory D. Sepich-Poore, Fyza Shaikh, Randy F. Sweis, Giorgio Trinchieri, Marcel van den Brink, Rinse K. Weersma, Katrine Whiteson, Liping Zhao, Jennifer McQuade, Hassane Zarour, Laurence Zitvogel

Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs

6 Citations (Scopus)

Résumé

Over the last decade, the composition of the gut microbiota has been found to correlate with the outcomes of cancer patients treated with immunotherapy. Accumulating evidence points to the various mechanisms by which intestinal bacteria act on distal tumors and how to harness this complex ecosystem to circumvent primary resistance to immune checkpoint inhibitors. Here, we review the state of the microbiota field in the context of melanoma, the recent breakthroughs in defining microbial modes of action, and how to modulate the microbiota to enhance response to cancer immunotherapy. The host-microbe interaction may be deciphered by the use of “omics” technologies, and will guide patient stratification and the development of microbiota-centered interventions. Efforts needed to advance the field and current gaps of knowledge are also discussed.

langue originale	Anglais
Pages (de - à)	16-34
Nombre de pages	19
journal	Cancer Cell
Volume	42
Numéro de publication	1
Les DOIs	https://doi.org/10.1016/j.ccell.2023.12.003
état	Publié - 8 janv. 2024

Accès au document

10.1016/j.ccell.2023.12.003

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Routy, B., Jackson, T., Mählmann, L., Baumgartner, C. K., Blaser, M., Byrd, A., Corvaia, N., Couts, K., Davar, D., Derosa, L., Hang, H. C., Hospers, G., Isaksen, M., Kroemer, G., Malard, F., McCoy, K. D., Meisel, M., Pal, S., Ronai, Z., ... Zitvogel, L. (2024). Melanoma and microbiota: Current understanding and future directions. Cancer Cell, 42(1), 16-34. https://doi.org/10.1016/j.ccell.2023.12.003

@article{b21cf84b24314452b7c92d884226c2a7,

title = "Melanoma and microbiota: Current understanding and future directions",

abstract = "Over the last decade, the composition of the gut microbiota has been found to correlate with the outcomes of cancer patients treated with immunotherapy. Accumulating evidence points to the various mechanisms by which intestinal bacteria act on distal tumors and how to harness this complex ecosystem to circumvent primary resistance to immune checkpoint inhibitors. Here, we review the state of the microbiota field in the context of melanoma, the recent breakthroughs in defining microbial modes of action, and how to modulate the microbiota to enhance response to cancer immunotherapy. The host-microbe interaction may be deciphered by the use of “omics” technologies, and will guide patient stratification and the development of microbiota-centered interventions. Efforts needed to advance the field and current gaps of knowledge are also discussed.",

author = "Bertrand Routy and Tanisha Jackson and Laura M{\"a}hlmann and Baumgartner, {Christina K.} and Martin Blaser and Allyson Byrd and Nathalie Corvaia and Kasey Couts and Diwakar Davar and Lisa Derosa and Hang, {Howard C.} and Geke Hospers and Morten Isaksen and Guido Kroemer and Florent Malard and McCoy, {Kathy D.} and Marlies Meisel and Sumanta Pal and Ze'ev Ronai and Eran Segal and Sepich-Poore, {Gregory D.} and Fyza Shaikh and Sweis, {Randy F.} and Giorgio Trinchieri and {van den Brink}, Marcel and Weersma, {Rinse K.} and Katrine Whiteson and Liping Zhao and Jennifer McQuade and Hassane Zarour and Laurence Zitvogel",

note = "Publisher Copyright: {\textcopyright} 2023",

year = "2024",

month = jan,

day = "8",

doi = "10.1016/j.ccell.2023.12.003",

language = "English",

volume = "42",

pages = "16--34",

journal = "Cancer Cell",

issn = "1535-6108",

number = "1",

}

Routy, B, Jackson, T, Mählmann, L, Baumgartner, CK, Blaser, M, Byrd, A, Corvaia, N, Couts, K, Davar, D, Derosa, L, Hang, HC, Hospers, G, Isaksen, M, Kroemer, G, Malard, F, McCoy, KD, Meisel, M, Pal, S, Ronai, Z, Segal, E, Sepich-Poore, GD, Shaikh, F, Sweis, RF, Trinchieri, G, van den Brink, M, Weersma, RK, Whiteson, K, Zhao, L, McQuade, J, Zarour, H & Zitvogel, L 2024, 'Melanoma and microbiota: Current understanding and future directions', Cancer Cell, VOL. 42, Numéro 1, p. 16-34. https://doi.org/10.1016/j.ccell.2023.12.003

TY - JOUR

T1 - Melanoma and microbiota

T2 - Current understanding and future directions

AU - Routy, Bertrand

AU - Jackson, Tanisha

AU - Mählmann, Laura

AU - Baumgartner, Christina K.

AU - Blaser, Martin

AU - Byrd, Allyson

AU - Corvaia, Nathalie

AU - Couts, Kasey

AU - Davar, Diwakar

AU - Derosa, Lisa

AU - Hang, Howard C.

AU - Hospers, Geke

AU - Isaksen, Morten

AU - Kroemer, Guido

AU - Malard, Florent

AU - McCoy, Kathy D.

AU - Meisel, Marlies

AU - Pal, Sumanta

AU - Ronai, Ze'ev

AU - Segal, Eran

AU - Sepich-Poore, Gregory D.

AU - Shaikh, Fyza

AU - Sweis, Randy F.

AU - Trinchieri, Giorgio

AU - van den Brink, Marcel

AU - Weersma, Rinse K.

AU - Whiteson, Katrine

AU - Zhao, Liping

AU - McQuade, Jennifer

AU - Zarour, Hassane

AU - Zitvogel, Laurence

PY - 2024/1/8

Y1 - 2024/1/8

N2 - Over the last decade, the composition of the gut microbiota has been found to correlate with the outcomes of cancer patients treated with immunotherapy. Accumulating evidence points to the various mechanisms by which intestinal bacteria act on distal tumors and how to harness this complex ecosystem to circumvent primary resistance to immune checkpoint inhibitors. Here, we review the state of the microbiota field in the context of melanoma, the recent breakthroughs in defining microbial modes of action, and how to modulate the microbiota to enhance response to cancer immunotherapy. The host-microbe interaction may be deciphered by the use of “omics” technologies, and will guide patient stratification and the development of microbiota-centered interventions. Efforts needed to advance the field and current gaps of knowledge are also discussed.

AB - Over the last decade, the composition of the gut microbiota has been found to correlate with the outcomes of cancer patients treated with immunotherapy. Accumulating evidence points to the various mechanisms by which intestinal bacteria act on distal tumors and how to harness this complex ecosystem to circumvent primary resistance to immune checkpoint inhibitors. Here, we review the state of the microbiota field in the context of melanoma, the recent breakthroughs in defining microbial modes of action, and how to modulate the microbiota to enhance response to cancer immunotherapy. The host-microbe interaction may be deciphered by the use of “omics” technologies, and will guide patient stratification and the development of microbiota-centered interventions. Efforts needed to advance the field and current gaps of knowledge are also discussed.

UR - http://www.scopus.com/inward/record.url?scp=85181838794&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2023.12.003

DO - 10.1016/j.ccell.2023.12.003

M3 - Review article

C2 - 38157864

AN - SCOPUS:85181838794

SN - 1535-6108

VL - 42

SP - 16

EP - 34

JO - Cancer Cell

JF - Cancer Cell

IS - 1

ER -